Acta Oncologica · 2002 · 12 citations · 19 references
MedicineHematologyOncologyChemotherapyClinical ImmunologyHematologic OncologyAntiretroviral TherapyChemotherapy In Hematologic MalignanciesImmunodeficiency DisordersHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyHiv-associated Lymphoid NeoplasmsImmune Reconstitution After Antiretroviral TherapyKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma Treatment
Twenty cases of systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients were reviewed over a 10-year-period, divided into Group A, including 13 NHL cases treated before the highly active antiretroviral therapy (HAART) era, and Group B, including 7 patients who received HAART. A Kaplan-Meier survival curve was performed and log-rank was applied to assess statistical differences between the groups. In group A, the median CD4 count was 36 cells/mm3. No complete remission was found. In group B, the median CD4 count was 137 cells/mm3. Four patients (57.0%) are still alive and in complete remission. Group A had a median survival of 5 months and group B 31 months (p = 0.0032). Our results are in agreement with recent reports in that a higher CD4 count and better immune status achieved with HAART is predictive of a better outcome. We found that HAART in combination with chemotherapy improves overall survival of NHL patients without increasing adverse effects.
19
Report of the Committee on Hodgkin's Disease Staging Classification.
Paul P. Carbone, Henry S. Kaplan, K. Musshoff et al. · PubMed · 1971 · 4.2K citations
Scott M. Hammer, Kathleen Squires, Michael D. Hughes et al. · New England Journal of Medicine · 1997 · 2.7K citations · Full text
Nancy L. Harris, Elaine S. Jaffe, J Diébold et al. · Modern Pathology · 2000 · 401 citations · Full text
Medicine, Hematology, Oncology +13
Lawrence D. Kaplan, David J. Straus, Marcia A. Testa et al. · New England Journal of Medicine · 1997 · 378 citations · Full text
Medicine, Hematology, Oncology +17